Keith Ward

Keith Ward has extensive experience in the pharmaceutical industry, with a focus on research and development. Keith is currently serving as the President, Chief Executive Officer, and Chairman of Kuria Therapeutics. Prior to that, they held the role of President and CEO at InterveXion Therapeutics, where they developed novel treatments for methamphetamine addiction and overdose. Keith has also served as a Board Member at Skye Bioscience Inc. and Cuda Pharmaceuticals, LLC. Keith has held strategic advisory roles at VIC Technology Venture Development and served as a Chief Development Advisor at Unicycive Therapeutics Inc. Keith's previous experience includes serving as the Chief Development Officer at Reata Pharmaceuticals and holding leadership positions at Bausch & Lomb and GlaxoSmithKline. Keith began their career as a Post-Doctoral Fellow at the U.S. Environmental Protection Agency. Keith's expertise lies in drug metabolism and pharmacokinetics, preclinical development, intellectual property, and project management.

Keith Ward obtained a Bachelor's degree in Toxicology from the University of Louisiana Monroe, where they studied from 1987 to 1991. Afterward, they pursued their Ph.D. in Toxicology at the University of North Carolina at Chapel Hill, completing their studies between 1991 and 1996.